Vaccine composition against Chlamydiaceae infections
AssigneesCentre National de la Recherche Scientifique (CNRS), Universite Paris Diderot—Paris 7, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsPhilippe Verbeke, Colette Kanellopoulos
Life of this patent
Estimating the term…
Abstract
The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
Claims5
A method of treating infections caused by Chlamydia bacteria selected in the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis, comprising:
- administering to a subject in need thereof a composition comprising a therapeutically effective amount of an inactivated BL form of Chlamydia bacteria selected from the group consisting of Chlamydia muridarum, Chlamydia pneumoniae, Chlamydia psitacci, Chlamydia abortus, Chlamydia felis, Chlamydia caviae, Chlamydia pecorum, Chlamydia suis and Chlamydia trachomatis,
- wherein the inactivated BL form of Chlamydia bacteria has been previously inactivated by treating with a β-lactam, wherein the β-lactam is selected from the group consisting of amoxicillin, benzylpenicillin, phenoxymethylpenicillin, cloxacillin, cefadroxil, cefixime, imipenem, mecillinam, clavulanic acid, tazobactam, sulbactam, and the combination of cefixime and imipenem.
Dependencies are inferred from the claim text.